Viewing data from:

NEO-POLYCIN

ANDA

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | A060427 | DOW PHARMACEUTICAL CORP SUB DOW CHEMICAL CO

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Neo-Polycin (2023)

Total Spending

$1K

Total Claims

Beneficiaries

Avg Cost/Unit

$9.53

Spending Trend

$153K(2019)→$9K(2020)→$2K(2021)→$901.49(2022)→$1K(2023)

YoY Change:-0.1%

5yr CAGR:-1.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML

0 patents0 exclusivities▴

SOLUTION/DROPS;OPHTHALMIC | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.